Sotuletinib

Sotuletinib (BLZ945) is a potent, selective, orally active and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs. Sotuletinib can be used for microglia depletion, and for tumor and CNS-related disease research[1][2][3][4].

Product Specifications

CAS Number

[953769-46-5]

Product Name Alternative

BLZ945

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

C-Fms

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Infection; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/BLZ945.html

Purity

99.97

Solubility

DMSO : 83.33 mg/mL (ultrasonic)

Smiles

O=C(C1=NC=CC(OC2=CC=C3N=C(N[C@H]4[C@H](O)CCCC4)SC3=C2)=C1)NC

Molecular Formula

C20H22N4O3S

Molecular Weight

398.48

Precautions

H302, H315, H319, H335

References & Citations

[1]Pyonteck SM, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013 Oct;19 (10) :1264-72.|[2]Strachan DC, et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells. Oncoimmunology. 2013 Dec 1;2 (12) :e26968.|[3]Chen Y, et al. Spatiotemporally selective astrocytic ATP dynamics encode injury information sensed by microglia following brain injury in mice. Nat Neurosci. 2024 Aug;27 (8) :1522-1533.|[4]Frosch M, et al. Microglia-neuron crosstalk through Hex-GM2-MGL2 maintains brain homeostasis. Nature. 2025 Oct;646 (8086) :913-924. |[5]Beckmann N, et al. Brain region-specific enhancement of remyelination and prevention of demyelination by the CSF1R kinase inhibitor BLZ945. Acta Neuropathol Commun. 2018 Feb 15;6 (1) :9.